The dose is usually 10 to 20 milligrams (mg) per kilogram (kg) of body weight every 12 hours for 10 to 21 days. However, the dose is usually not more than 750 mg per day. However, the dose is usually not more than 750 mg per day. Some patients may need a double dose of the initial to reach values within the therapeutic range. When you remove the antibacterial, phenytoin should carefully adjusted to avoid poisoning by this substance. 10 to 12.5 mg/kg/dose PO every 12 hours (Max: 500 mg/dose) has been studied in low-risk outpatients and is often administered after initial IV therapy. Treatment is generally continued until fever is absent for 24 to 48 hours with a rising neutrophil count. Oral therapy for low-risk outpatients with quinolones is suggested by the American Society of Clinical Oncology; however, quinolones are. Indications. Daily dose in mg. Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin) Infections of the lower respiratory tract Detailed dosage guidelines and administration information for Cipro (ciprofloxacin hydrochloride). Includes dose adjustments, warnings and precautions. Some experts advocate giving an initial dose of a long-acting parenteral antimicrobial, such as a 1-g dose of ceftriaxone or a consolidated 24-hour dose of an aminoglycoside (eg one 5–7 mg/kg dose of gentamicin) in such situation. The aim of the present study was to obtain clinical experience with the use of high-dose ciprofloxacin as monotherapy for the treatment of febrile neutropenia episodes (granulocyte count, 500/mm 3) compared to a standard regimen and to clarify whether ciprofloxacin administration may be switched to the oral route. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 1 -Dose and initial route of therapy should be based on severity of infection. -Due to an increased incidence of side effects compared to controls (including those related to joints and/or surrounding tissues), this drug is not a drug of first choice in pediatric patients. CIPRO® (ciprofloxacin hydrochloride) TABLETS CIPRO® (ciprofloxacin*) ORAL SUSPENSION 08918468, R.0 10/04 To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO®.